2 Information about patiromer
Marketing authorisation indication
2.1 Patiromer (Veltassa, Vifor Pharma) has a marketing authorisation in the UK 'for the treatment of hyperkalaemia in adults'.
Dosage in the marketing authorisation
2.2 Patiromer is administered orally. The recommended starting dose is 8.4 g once a day and the maximum dose is 25.2 g. The dose can be increased or decreased after a minimum interval of 1 week based on serum potassium levels. The dose should be reduced or stopped if serum potassium is below the desired range. Patiromer should be taken with or without food and separated by 3 hours from other oral medication. The onset of action for patiromer is 4 to 7 hours and patiromer should not replace emergency treatment for life-threatening hyperkalaemia.